Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
... Company Also Receives Going Concern Audit Opinion ISELIN, N.J., March 6 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today that it has received a Nasdaq Staff Determination that the company is not in compliance with the minimum $2,500,000 stockholders' eq...Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
... ISELIN, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today announced that it received notice from The Nasdaq Stock Market ("Nasdaq") on November 11, 2008 that the Company is not in compliance with Nasd...Pharmos Corporation Reports 2008 Third Quarter Results
... ISELIN, N.J., Nov. 6 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today reported results for the third quarter ended September 30, 2008. The Company recorded a net loss of $2.8 million, or $0.11 per share, for the ...Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
... ISELIN, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today reported financial results for the fourth quarter and twelve-month period and ended December 31, 2007. Fourth Quarter Ended December 31, 200...The Republic of Slovenia Selects Autonomy Meridio for WTO's Health Initiative
...itutions in the phytosanitary field, as well as their control. As a result, pars compiles and manages a large volume of reports, analysis, information and o...k. To better manage and store this growing volume of documents and records, pars selected Autonomy Meridio to provide a highly secure, flexible and scalable...UAB research could improve the prognosis and treatment of lung cancer
... This release is available in Spanish . A group of scientists led by Professor Xavier pars of the Department of Biochemistry and Molecular Biology at Universitat Autnoma de Barcelona, has published a research on AKR1B10, an enzyme that is de...Pharmos Restructures Operations in Israel
... ISELIN, N.J., Oct. 30 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today it is undertaking a second phase of restructuring as it continues to optimize the balance between cash resources and its most promis...Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
... Study did not achieve statistical significance ISELIN, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today announced results from its Phase 2a clinical trial of its topical NanoEmulsion (NE) drug delivery technology formulated with 3% Diclofenac Die...Ahmed Glaucoma Valve (small size) with Pars Plana Clip
Description: Ahmed Glaucoma Valve (small size) with Pars Plana Clip ....Ahmed Glaucoma Valve with Pars Plana Clip
Description: Ahmed Glaucoma Valve with Pars Plana Clip....Baerveldt Pars Plan Glaucoma Implant
Description: Baerveldt Pars Plana glaucoma implant is the first glaucoma implant designed for effective placement during or following a pars plana vitrectomy. The Hoffman Elbow was specifically designed for insertion through a 20 gauge pars plana sclerostemy incision. Baerveldt Glaucoma Implants are a significa...The Sabet Lenticular Safety Net
Description:...s Spatula To Reach Into The Vitreous Cavity To Salvage Lens Fragments With One Instrument. A 23g Tube Fits Through A 1mm Paracentesis Or pars Plana Incision, And When Opened Inside The Eye, Provides A Large Surface Area For Fragment Support. Thin And Sturdy Wires Minimize Traction In T...Contact Wide Field Panoramic Viewing
Description:...ing. The average observation field for either lens is 130 degrees. Slight tilting of the lenses make the who area between the posterior pole and the pars plana visible. Fluid gas exchanges are easily imaged. This type of viewing system is usually recommended for the budget minded clinic....Songer Cable Cervical Thoracic System
Description:...ical interspinous, triple-wire, or facet cabling techniques. Thoraco-lumbar translation and anchoring in deformity constructs. Direct repair of lumbar pars interarticularis defects....UCLA imaging study of children with autism finds broken mirror neuron system
...the Autism Diagnostic Interview). The study shows that unlike typically developing children, children with autism have virtually no activity in the pars opercularis of the inferior frontal gyrus, identified by previous research as a key part of the mirror neuron system. Importantly, the level of mirror...Pharmos Corporation Reports 2008 Fourth Quarter Results
... ISELIN, N.J., Feb. 27 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today reported financial results for the fourth quarter and twelve-month period ended December 31, 2008. Fourth Quarter Ended December 31, 200...Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists
... ISELIN, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today that it has entered into an agreement with an Israel based company, Reperio Pharmaceuticals Ltd. (Reperio) for the sale of the paten...Pharmos Corporation Announces That it Will Cease Operations in Israel
... ISELIN, N.J., Aug. 29 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today announced that effective October 31, 2008 it will cease operations in Rehovot, Israel, and manage those activities currently based in Rehovot ...Pharmos Corporation Reports 2008 Second Quarter Results
... ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today reported results for the second quarter ended June 30, 2008. The Company recorded a net loss of $2.7 million, or $0.10 per share, for the seco...Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
... ISELIN, N.J., May 14 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today that its President and Chief Financial Officer, S. Colin Neill, will present at the Rodman & Renshaw 5th Annual Global Healthcare Co...Pharmos Corporation Reports 2008 First Quarter Results
... ISELIN, N.J., May 8 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) today reported results for the first quarter ended March 31, 2008. The Company recorded a net loss of $3.6 million, or $0.14 per share, for the firs...Pharmos Corporation Completes Initial Closing of Private Placement
... ISELIN, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today that it has completed an initial closing of a private placement of its 10% Convertible Debentures due November 2012. At the initial ...Pharmos Corporation Announces Board and Management Changes
...hairman of the Board S. Colin Neill Named President ISELIN, N.J., Jan. 3 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today certain changes in its Board of Directors and Management, effective immediately. Board Changes Robert F. Johnston has been elect...Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
... ISELIN, N.J., Dec. 18 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today that President & COO Alan Rubino has elected to resign from the Company. Mr. Rubino joined Pharmos in November 2005 and was instru...Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
... Company Selected to Participate in Gastroenterology Panel Discussion ISELIN, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: pars ) announced today that Chief Executive Officer Elkan R. Gamzu, Ph.D. will participate in a gastroenterology-focused panel discussion at the 2007 RBC C...